# A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

> **NCT06508216** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dato-DXd
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06508216
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-05
- **Primary completion:** 2025-12-17
- **Final completion:** 2027-12-17
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508216, "A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06508216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*